Australian Pharmaceutical Industries Ltd · Valuation
ASX: API · Health Care · Health Care Distributors
No model estimate available for API right now
Craytheon's models need several years of financial history before producing a fair-value estimate for Australian Pharmaceutical Industries Ltd.
Discounted cash flow
the recent free cash flow record doesn't support a reliable projection.
EPS growth model
it needs a longer record of earnings and market prices.
P/E multiple
it needs a longer record of earnings and market prices.
Trailing P/E history
Monthly price ÷ trailing diluted EPS · extremes above 100 excluded from stats
Per-share fundamentals
The inputs behind the models
| FY | EPS | Book value / sh | Free cash flow |
|---|---|---|---|
| 2021 | $0.00 | $0.89 | $25.9M |
| 2020 | $-0.02 | $0.93 | $11.1M |
| 2019 | $0.11 | $1.05 | $-152.2M |
| 2018 | $0.10 | $1.00 | $-108.0M |
| 2017 | $0.11 | $1.12 | $-56.1M |
| 2016 | $0.11 | $1.09 | $-32.6M |
| 2015 | $0.09 | $1.02 | $-60.5M |
| 2014 | $-0.19 | $0.98 | $34.1M |
| 2013 | $0.05 | $1.20 | $41.5M |
| 2012 | $0.06 | $1.16 | $28.0M |
Looking for value across the whole market? The ASX screener lists every covered company trading below our fair-value models, refreshed each trading day.
What did valuation models estimate Australian Pharmaceutical Industries (API) was worth before it stopped trading?
Australian Pharmaceutical Industries (API) no longer trades on the ASX, so there is no current share price to weigh against any model output; the last recorded close was $1.02 on 28 September 2020, and this section reflects that historical record rather than an active valuation.
Specific fair-value figures from valuation models were not disclosed in the reported figures beyond a valuation date of 8 March 2026, so no per-share estimate can be presented here. Earnings, which underpin most valuation approaches, were volatile across the period, with diluted EPS ranging from a loss of $0.19 in FY2014 to a high of $0.11 in FY2016, FY2017 and FY2019, before falling to just $0.0023 in FY2021.
Because EPS was negative in FY2020 (-$0.0161), the year closest to the last recorded price, a price-to-earnings ratio for that point could not be meaningfully calculated, and a five-year median P/E was not disclosed in the reported figures. Any valuation comparison for this company would need to rely on the earnings trend on record rather than a live market price.
AI-assisted analysis generated from Craytheon's verified financial data · Updated 4 Jul 2026 · How this works
Data is general information only, not financial advice. Figures are as reported in company filings (some ASX companies report in USD); share prices are AUD.